Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system.
Black or African American
/ statistics & numerical data
Aged
Cohort Studies
Data Management
/ statistics & numerical data
Delivery of Health Care
/ statistics & numerical data
Health Services Accessibility
/ statistics & numerical data
Hispanic or Latino
/ statistics & numerical data
Humans
Income
/ statistics & numerical data
Longitudinal Studies
Male
Middle Aged
Prostate-Specific Antigen
/ metabolism
Prostatectomy
/ statistics & numerical data
Prostatic Neoplasms
/ mortality
White People
/ statistics & numerical data
disparities
health services research
prostate cancer
race
veterans
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
21
08
2019
revised:
04
10
2019
accepted:
14
11
2019
pubmed:
28
1
2020
medline:
11
11
2020
entrez:
28
1
2020
Statut:
ppublish
Résumé
African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non-Hispanic white (NHW) men. The authors hypothesized that receiving care through the Veterans Affairs (VA) health system, an equal-access medical system, would attenuate this disparity. A longitudinal, centralized database of >20 million veterans was used to assemble a cohort of 60,035 men (18,201 AA men [30.3%] and 41,834 NHW men [69.7%]) who were diagnosed with PC between 2000 and 2015. AA men were more likely to live in regions with a lower median income ($40,871 for AA men vs $48,125 for NHW men; P < .001) and lower high school graduation rates (83% for AA men vs 88% for NHW men; P < .001). At the time of diagnosis, AA men were younger (median age, 63.0 years vs 66.0 years; P < .001) and had a higher prostate-specific antigen level (median, 6.7 ng/mL vs 6.2 ng/mL; P < .001), but were less likely to have Gleason score 8 to 10 disease (18.8% among AA men vs 19.7% among NHW men; P < .001), a clinical T classification ≥3 (2.2% vs 2.9%; P < .001), or distant metastatic disease (2.7% vs 3.1%; P = 0.01). The 10-year PC-specific mortality rate was slightly lower for AA men (4.4% vs 5.1%; P = .005), which was confirmed in multivariable competing-risk analysis (subdistribution hazard ratio, 0.85; 95% CI, 0.78-0.93; P < .001). AA men diagnosed with PC in the VA health system do not appear to present with more advanced disease or experience worse outcomes compared with NHW men, in contrast to national trends, suggesting that access to care is an important determinant of racial equity.
Sections du résumé
BACKGROUND
African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non-Hispanic white (NHW) men. The authors hypothesized that receiving care through the Veterans Affairs (VA) health system, an equal-access medical system, would attenuate this disparity.
METHODS
A longitudinal, centralized database of >20 million veterans was used to assemble a cohort of 60,035 men (18,201 AA men [30.3%] and 41,834 NHW men [69.7%]) who were diagnosed with PC between 2000 and 2015.
RESULTS
AA men were more likely to live in regions with a lower median income ($40,871 for AA men vs $48,125 for NHW men; P < .001) and lower high school graduation rates (83% for AA men vs 88% for NHW men; P < .001). At the time of diagnosis, AA men were younger (median age, 63.0 years vs 66.0 years; P < .001) and had a higher prostate-specific antigen level (median, 6.7 ng/mL vs 6.2 ng/mL; P < .001), but were less likely to have Gleason score 8 to 10 disease (18.8% among AA men vs 19.7% among NHW men; P < .001), a clinical T classification ≥3 (2.2% vs 2.9%; P < .001), or distant metastatic disease (2.7% vs 3.1%; P = 0.01). The 10-year PC-specific mortality rate was slightly lower for AA men (4.4% vs 5.1%; P = .005), which was confirmed in multivariable competing-risk analysis (subdistribution hazard ratio, 0.85; 95% CI, 0.78-0.93; P < .001).
CONCLUSIONS
AA men diagnosed with PC in the VA health system do not appear to present with more advanced disease or experience worse outcomes compared with NHW men, in contrast to national trends, suggesting that access to care is an important determinant of racial equity.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1683-1690Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001443
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 American Cancer Society.
Références
Steele CB, Li J, Huang B, Weir HK. Prostate cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5160-5177.
Noone AM, Howlader N, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2015. National Cancer Institute; 2018.
Bhardwaj A, Srivastava SK, Khan MA, et al. Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed). 2017;22:772-782.
Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4(suppl 1):S2.
Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68:927-936.
Yamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol. 2015;33:2789-2796.
Friedlander DF, Trinh QD, Krasnova A, et al. Racial disparity in delivering definitive therapy for intermediate/high-risk localized prostate cancer: the impact of facility features and socioeconomic characteristics. Eur Urol. Published online August 1, 2017. doi:10.1016/j.eururo.2017.07.023
Lee DJ, Barocas DA, Zhao Z, et al. Contemporary prostate cancer radiation therapy in the United States: patterns of care and compliance with quality measures. Pract Radiat Oncol. 2018;8:307-316.
Stokes WA, Hendrix LH, Royce TJ, et al. Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study. Cancer. 2013;119:2486-2493.
Ziehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015;33:18.e17-18.e13.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018;124:752-759.
Mahal BA, Chen YW, Muralidhar V, et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017;28:1098-1104.
Kondo K, Low A, Everson T, et al. Prevalence of and Interventions to Reduce Health Disparities in Vulnerable Veteran Populations: A Map of the Evidence. VA ESP Project #05-225. US Department of Veterans Affairs; 2017.
US Department of Veterans Affairs. VA Informatics and Computing Infrastructure (VINCI). US Department of Veterans Affairs; 2018.
Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
Guo DP, Thomas IC, Mittakanti HR, et al. The research implications of prostate specific antigen registry errors: data from the Veterans Health Administration. J Urol. 2018;200:541-548.
Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
Kim B. Heirarchical Linear Regression. University of Virginia Library Research Data Services and Sciences; 2016.
Wickham H. tidyverse: Easily Install and Load the ‘Tidyverse’. tidyverse; 2017.
Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R Project for Statistical Computing; 2014.
Therneau TM, Grambsch PM. A Package for Survival Analysis in S. 2015.
Pannek J, Marks LS, Pearson JD, et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1998;159:449-453.
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.
Halabi S, Dutta S, Tangen CM, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol. 2019;37:403-410.
Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599-1605.
Hamilton RJ, Aronson WJ, Presti JC, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy. Cancer. 2007;110:2202-2209.
Freedland SJ, Vidal AC, Howard LE, et al; Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group. Race and risk of metastases and survival after radical prostatectomy: results from the SEARCH database. Cancer. 2017;123:4199-4206.
Dess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5:975-983.
Daley J. Ensuring timely access to quality care for US veterans. JAMA. 2018;319:439-440.
Aponte M, Garin T, Glasgow D. Minority Veterans Report. US Veterans Administration; 2017.
Ehrenstein V, Hernandez RK, Maegbaek ML, et al. Validation of algorithms to detect distant metastases in men with prostate cancer using routine registry data in Denmark. Clin Epidemiol. 2015;7:259-265.
Penn M, Bhatnagar S, Kuy S, et al. Comparison of wait times for new patients between the private sector and United States Department of Veterans Affairs Medical Centers. JAMA Netw Open. 2019;2:e187096.
Reddy A, Roberts R, Shenoy D, Packianathan S, Giri S, Vijayakumar S. Prostate cancer screening guidelines for African American veterans: a new perspective. J Natl Med Assoc. Published online November 5, 2018. doi:10.1016/j.jnma.2018.10.010
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:1914-1931.